CSL Behring lung drug would cost NHS £8m per patient, says NICENICE has rejected CSL Behring’s alpha1-proteinase inhibitor Respreeza for treating genetic emphysema in draft guidance, saying that it Share XCSL Behring lung drug would cost NHS £8m per patient, says NICEhttps://pharmaphorum.com/news/csl-behring-lung-drug-would-cost-nhs-8m-per-patient-says-nice/
Could digital technology revolutionise pharma in 2018?This year’s eyeforpharma conference in Barcelona outlined how 2018 could be a turning point for the industry. As Share XCould digital technology revolutionise pharma in 2018?https://pharmaphorum.com/views-and-analysis/digital-technology-revolutionise-pharma-2018/
